New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for […]
Theratechnologies received FDA approval for EGRIFTA WR™ (Tesamorelin F8), a new, weekly reconstitution formulation of tesamorelin for injection, to treat excess visceral abdominal fat in adults with HIV and lipodystrophy. It will replace EGRIFTA SV ®.
